Scarica l'app Stockscreener
1.60
3.61%
-0.06
Dopo l'orario di chiusura:
1.58
-0.02
-1.25%
Precedente Chiudi:
$1.66
Aprire:
$1.62
Volume 24 ore:
14,269
Relative Volume:
0.12
Capitalizzazione di mercato:
$18.77M
Reddito:
-
Utile/perdita netta:
$-3.15M
Rapporto P/E:
-5.2425
EPS:
-0.3052
Flusso di cassa netto:
$-2.23M
1 W Prestazione:
-13.51%
1M Prestazione:
-18.37%
6M Prestazione:
-23.08%
1 anno Prestazione:
-41.08%
Intervallo 1D:
$1.585
$1.6386
Intervallo di 1 settimana:
$1.50
$1.85
Portata 52W:
$1.50
$4.0499
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Nome
Cytomed Therapeutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GDTC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
1.60 | 19.48M | 0 | -3.15M | -2.23M | -0.3052 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytomed Therapeutics Ltd Borsa (GDTC) Ultime notizie
CytoMed stock jumps after announcing clinical trial partnership in Malaysia By Investing.com - Investing.com South Africa
CytoMed stock jumps after announcing clinical trial partnership in Malaysia - Investing.com India
CytoMed Therapeutics enters clinical trial agreement with Malaysian hospital - Investing.com
CytoMed Therapeutics enters clinical trial agreement with Malaysian hospital By Investing.com - Investing.com South Africa
CytoMed Therapeutics (NASDAQ: GDTC) plans first-in-human gamma delta T cell trial in Malaysia - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) to run first-in-human Malaysia trial of donor-derived γδ T cells - Stock Titan
CytoMed Therapeutics (GDTC) Stock Analysis Report | Financials & Insights - Benzinga
Why CytoMed Therapeutics Limited (F98) stock appears on watchlists2025 Price Momentum & Reliable Trade Execution Plans - Newser
Will CytoMed Therapeutics Limited (F98) stock benefit from Fed rate cuts2025 Short Interest & Intraday High Probability Setup Alerts - Newser
CytoMed acquires T Cell technology from UK to treat cancers in China and India - BioSpectrum Asia
CytoMed Therapeutics acquires T Cell technology from UK to treat cancers in China and India - BioSpectrum Asia
Applying Wyckoff theory to CytoMed Therapeutics Limited stock2025 Trade Ideas & Weekly Hot Stock Watchlists - newser.com
What earnings margins imply for CytoMed Therapeutics Limited (F98) stockQuarterly Trade Review & AI Driven Stock Movement Reports - newser.com
How CytoMed Therapeutics Limited stock reacts to job market dataPortfolio Update Summary & Daily Technical Stock Forecast Reports - newser.com
Can you recover from losses in CytoMed Therapeutics LimitedTrade Risk Report & AI Driven Stock Reports - newser.com
CytoMed Therapeutics Ltd (GDTC) can make a big difference with a little luck - Setenews
Will CytoMed Therapeutics Limited stock outperform Dow Jones indexJuly 2025 Short Interest & Entry Point Confirmation Alerts - newser.com
Why CytoMed Therapeutics Limited stock remains a top recommendationWatch List & Safe Entry Point Identification - newser.com
CytoMed acquires TC BioPharm’s gamma delta T cell technology By Investing.com - Investing.com Canada
How dovish Fed policy supports CytoMed Therapeutics Limited (F98) stock - newser.com
Can CytoMed Therapeutics Limited (F98) stock resist broad market declinesMarket Risk Summary & Daily Profit Focused Stock Screening - newser.com
What insider trading reveals about CytoMed Therapeutics Limited stockQuarterly Trade Review & High Win Rate Trade Tips - newser.com
Will CytoMed Therapeutics Limited (F98) stock maintain strong growthProduct Launch & Stepwise Trade Signal Implementation - newser.com
CytoMed acquires TC BioPharm's gamma delta T cell technology By Investing.com - Investing.com Nigeria
[6-K] CytoMed Therapeutics Ltd Current Report (Foreign Issuer) | GDTC SEC FilingForm 6-K - Stock Titan
Royal Caribbean (NYSE: RCL) launches unsecured notes sale to finance Celebrity Xcel - Stock Titan
Is CytoMed Therapeutics Limited (F98) stock a fit for income portfoliosMarket Risk Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Will CytoMed Therapeutics Limited (F98) stock keep high P E multiples2025 Key Lessons & Weekly Top Stock Performers List - newser.com
Is a relief rally coming for CytoMed Therapeutics Limited holdersMarket Activity Summary & Fast Gain Swing Alerts - newser.com
CytoMed Therapeutics Limited recovery potential after sell offJuly 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - newser.com
Is CytoMed Therapeutics Limited (F98) stock undervalued historically2025 Market Outlook & Risk Managed Investment Signals - newser.com
How to monitor CytoMed Therapeutics Limited with trend dashboardsJuly 2025 Weekly Recap & Safe Swing Trade Setups - newser.com
Is CytoMed Therapeutics Limited stock attractive for income investorsMarket Risk Summary & Community Consensus Picks - newser.com
Is CytoMed Therapeutics Limited stock vulnerable to regulatory risksJuly 2025 Momentum & Technical Pattern Based Signals - newser.com
GDTC Stock Institutional Owners - Quiver Quantitative
CytoMed Therapeutics Limited (GDTC) Stock Price, News, Quote & History - Yahoo! Finance Canada
There is no way CytoMed Therapeutics Ltd (GDTC) can keep these numbers up - setenews.com
CytoMed Therapeutics secures $500,000 investment for subsidiary By Investing.com - Investing.com Nigeria
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy - The Manila Times
CytoMed Therapeutics Secures Non-Dilutive Investment for - GlobeNewswire
Cytomed Therapeutics Ltd Azioni (GDTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):